HSTO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HSTO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Histogen's Trailing 12-Month Free Cash Flow is $-10.08 Mil, and Market Cap is $1.50 Mil. Therefore, Histogen's FCF Yield % for today is -672.11%.
The historical rank and industry rank for Histogen's FCF Yield % or its related term are showing as below:
During the past 4 years, the highest FCF Yield % of Histogen was -9.54%. The lowest was -1571.21%. And the median was -125.48%.
Histogen's FCF Margin % for the quarter that ended in Sep. 2023 was -53,780.00%.
The historical data trend for Histogen's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Histogen Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
FCF Yield % | - | -106.23 | -88.90 | -279.19 |
Histogen Quarterly Data | ||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
FCF Yield % | Get a 7-Day Free Trial | -170.56 | -275.27 | -197.34 | -315.51 | -489.30 |
For the Biotechnology subindustry, Histogen's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Histogen's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Histogen's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Histogen's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -9.899 | / | 3.5455608 | |
= | -279.19% |
Histogen's annualized FCF Yield % for the quarter that ended in Sep. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -2.689 | * | 4 | / | 2.198247696 | |
= | -489.30% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Histogen FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Histogen's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Joyce Reyes | officer: See Remarks | 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121 |
Richard W Pascoe | director, officer: See Remarks | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Rochelle Fuhrmann | director | C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866 |
Susan Richards Windham-bannister | director | 78 BLANCHARD ROAD, BURLINGTON MA 01803 |
Moya Daniels | officer: See Remarks | 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121 |
Susan A. Knudson | officer: See Remarks | 9191 TOWNE CENTRE DRIVE, SUITE 400, SAN DIEGO CA 92121 |
Jonathan Jackson | director, 10 percent owner | C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121 |
Gail K Naughton | officer: See Remarks | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
David Hugh Crean | director | C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121 |
Stephen Chang | director | 12912 CAMINO DEL VALLE, POWAY CA 92064 |
Brian Satz | director | C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121 |
Yizhuo Zhang | director | C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121 |
Martin Latterich | officer: See Remarks | C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121 |
Steven J Mento | director | C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804 |
Keith W Marshall | officer: EVP, COO & CFO | C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-11-2022
By GuruFocusNews GuruFocusNews • 06-06-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By PurpleRose PurpleRose • 07-11-2022
By GuruFocusNews GuruFocusNews • 05-22-2022
By PurpleRose PurpleRose • 07-14-2022
By GuruFocusNews GuruFocusNews • 06-11-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
By GuruFocusNews GuruFocusNews • 06-16-2022
By GuruFocusNews GuruFocusNews • 04-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.